Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 50%GRADE not reported 2 · 33.3%Very low 1 · 16.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Amifostine vs no otoprotective intervention

Quality of life · children with cancer treated with platinum‐based therapy

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amifostine vs no otoprotective intervention

Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy

The review found no eligible studies for this question.

1 finding from 1 review

Medical interventions for the prevention of platinum‐induced hearing loss in children with cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amifostine vs no treatment/placebo

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine showed no clear difference in quality of life compared with no treatment/placebo; GRADE not reported.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT; up to 3 months postRT
MD 0.52 [-0.02, 1.06]
1 study · 233 participants
GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
No data on either quality of life or other oral related symptoms were reported.
0 studies
No studies found

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
End of RT and 6, 12, 18, 24 months postRT
No significant differences between the three treatment arms (Jellema 2006)
1 study
GRADE not reported

Amifostine vs no treatment/placebo

Quality of life (Patient Benefit Questionnaire, 10-point scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

It is very uncertain whether amifostine changes quality of life (Patient Benefit Questionnaire, 10-point scale) compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 months postRT
MD 0.70 [0.20, 1.20]
1 study · 180 participants
Very low